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are right now with this technology, what length uncovered stent
do you currently favor when you’re approaching a patient?
Dr Joseph V. Lombardi (Camden, NJ). Based on the data
that we’re seeing now, we’re observing a lot of increased false
lumen ﬂow. I think the natural tendency of everyone is to increase
your coverage zone down to the celiac artery for your proximal
piece. However, the STABLE trial has demonstrated a very low
1.2% paraplegia rate and I think one of the advantages of using
one short-body TX2 device followed by a long bare stent. Theoret-
ically, the observed enhanced false lumen ﬂow has minimized para-
plegia and combined with low mortality rates, it seems to do the
job while minimizing complications.
As far as the bare stent, from my standpoint, I think it comes
down to what your patient looks like anatomically. If they have
extensive malperfusion distally, then I would extend that bare stent
all the way down to the bifurcation; if it looked like there was a
very focal area, then I would minimize its coverage.
Dr Jon Matsumura (Madison, Wisc). What is the deﬁnition
of thoracic versus abdominal aorta? Is it at the diaphragm? Is it
at the celiac? Does abdominal aorta growth mean that these pa-
tients will require a type IV thoraco-abdominal repair?
If the abdominal aorta is deﬁned at the celiac, have you modi-
ﬁed your treatment in that when you need to go back and treat pa-
tients with abdominal aortic growth either with another renal stent
or maybe an open repair, how do you feel about having the bare
aortic stent there? Do you feel like there is a different approach
you should do at that initial operation that might make that second
repair simpler?
Dr Lombardi. We deﬁne the thoracic aorta from the celiac
and above, abdominal is below, based on our core lab data, and
that’s how they measured our false lumen patency.
Now, if you have a bare metal stent crossing through the peri-
visceral aorta, which 80 of our patients had, and then you notice
growth, having that stent there approximates the intima with
your target visceral artery. So if you’re looking to bring back the
target vessel that has a reentry tear back in continuity with the
true lumen, it’s much easier with the bare stent present. Working
through that stent is pretty facile, just like a fenestrated stent graft
at the end of it all. There are smaller little intimal tears that are
from the intercostals that may persist; however, when you tackle
the large entry tears, you usually minimize ﬂow to the degree
where you can stabilize growth.
Dr Juan Parodi (San Isidro, Argentina). I have a question. It
seems that we don’t have solutions yet for the abdominal aorta in
the long term, and we see these more and more as we follow our
patients’ dilatation of the abdominal aorta in type IIIb. It seems
that with your system you can achieve positive remodeling of the
true lumen. The problem is the false lumen. We are conducting
studies in which we are seeing that the diastolic pressure in the false
lumen is higher than in the true lumen and through numerical
models, and, mechanical models and some anecdotal measure-
ments, we are seeing that we need another treatment to completethis, either do percutaneous septotomy or perhaps using branches
and complete the occlusion of the entry sites of the distal aorta.
What do you think about it?
Dr Lombardi. I believe that’s largely true. Persistent ﬂow in
the false lumen and the abdominal aorta is the Achilles’ heel and
responsible for growth. I think from a basic standpoint covering
the reentry tears and minimizing ﬂow into that segment has sub-
stantial value in the setting of growth. It’s more or less anecdotal
at this point because we don’t have a host of patients to really to
compare with those who did not achieve those procedures. Sec-
ondary procedures, particularly if patients are treated in the acute
phase, are going to be common to this pathology and
management.
Dr Manju Kalra (Rochester, Minn). I just have two quick
questions for you. Do you have a theoretical explanation for
why you had continued growth in the group of patients that
were treated in the acute phase within the ﬁrst 2 weeks
compared to those treated later? And do you think, when you
have a larger group of patients, you’re going to be able to
make a recommendation as to preferred timing of treatment
based on this data?
Dr Lombardi. That’s the question, isn’t it? From the stand-
point of patients with malperfusion and rupture, you have no
choice. So you’re treating them when they present. Most of the pa-
tients who present in the acute phase have those two problems. So
from a standpoint of watchful waiting, and potentially waiting after
14 days to treat them, that might provide you some value in pa-
tients in whom you think you can wait on, but again that clinical
scenario rarely will come up.
As to why it happens, I don’t know. I think that in the acute
phase there is inﬂammation and a very suggestible intimal mem-
brane which maybe you set off a course or a series of events where
the aorta just is unable to stabilize. But I don’t have a very good
explanation for that at this time. We clearly need to follow those
patients closely, however.
Dr B. Timothy Baxter (Omaha, Neb). It looked like your
rupture rate was higher in the growth group versus the no-growth
group. Where are the ruptures occurring in these patients, and is
there something that you could be looking for to try to prevent
the rupture?
Dr Lombardi. We were unable to get an autopsy on the pa-
tients who ruptured, so we really don’t know exactly where that
occurred anatomically. They presented with back pain and most
of them expired before we could fully evaluate the location of their
ruptures. But we suspect they were all in the thoracic aorta.
However, you mentioned the increased rate of rupture in pa-
tients in the thoracic aorta with growth; although not signiﬁcant,
we had an equally converse situation in the abdominal aorta where
the patients who had no growth had a higher mortality and
rupture. So that was a little counterintuitive, not something I
would have predicted; however, that’s how it worked out. So,
based on the data thus far, we can’t predict rupture based on
morphology and growth.
